abm-1310

ABM-1310 is a novel, orally administered small molecule inhibitor that selectively targets the BRAF(V600E) kinase. By binding to and inhibiting this mutant form of BRAF, ABM-1310 disrupts the overactive MAPK signaling pathway in tumor cells harboring BRAF V600 mutations, leading to reduced tumor cell proliferation. The drug is distinguished by its high selectivity for BRAF mutations, excellent water solubility, cell permeability, and notably strong blood-brain barrier penetration. These properties make it particularly promising for treating cancers with central nervous system involvement or brain metastases. ABM-1310 is being developed primarily by ABM Therapeutics for advanced solid tumors with BRAF V600 mutations—including glioblastoma and other primary CNS tumors—and has received orphan drug designation from the FDA for glioblastoma. Clinical trials have shown preliminary evidence of anticancer activity and a favorable safety profile in patients who have failed previous therapies targeting BRAF or MEK.

Other names

ABM 1310ABM1310ABM-1310